449 related articles for article (PubMed ID: 30692522)
1. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
2. Overcoming statin resistance in prostate cancer cells by targeting the 3-hydroxy-3-methylglutaryl-CoA-reductase.
Göbel A; Pählig S; Motz A; Breining D; Traikov S; Hofbauer LC; Rachner TD
Biochem Biophys Res Commun; 2024 May; 710():149841. PubMed ID: 38588613
[TBL] [Abstract][Full Text] [Related]
3. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
4. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
[TBL] [Abstract][Full Text] [Related]
5. HMG-CoA reductase degrader, SR-12813, counteracts statin-induced upregulation of HMG-CoA reductase and augments the anticancer effect of atorvastatin.
Zhou Y; Tashiro J; Kamatani S; Irie N; Suzuki A; Ishikawa T; Warita K; Oltvai ZN; Warita T
Biochem Biophys Res Commun; 2023 Oct; 677():13-19. PubMed ID: 37541087
[TBL] [Abstract][Full Text] [Related]
6. Role of hydroxymethylglutharyl-coenzyme A reductase in the induction of stem-like states in breast cancer.
Marks MP; Giménez CA; Isaja L; Vera MB; Borzone FR; Pereyra-Bonnet F; Romorini L; Videla-Richardson GA; Chasseing NA; Calvo JC; Vellón L
J Cancer Res Clin Oncol; 2024 Feb; 150(2):106. PubMed ID: 38418798
[TBL] [Abstract][Full Text] [Related]
7. Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Bjarnadottir O; Feldt M; Inasu M; Bendahl PO; Elebro K; Kimbung S; Borgquist S
Sci Rep; 2020 Jan; 10(1):558. PubMed ID: 31953433
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Lipkin SM; Chao EC; Moreno V; Rozek LS; Rennert H; Pinchev M; Dizon D; Rennert G; Kopelovich L; Gruber SB
Cancer Prev Res (Phila); 2010 May; 3(5):597-603. PubMed ID: 20403997
[TBL] [Abstract][Full Text] [Related]
9. Statin resistance in Candida glabrata.
Subhan M; Faryal R; Macreadie I
Biotechnol Lett; 2018 Oct; 40(9-10):1389-1394. PubMed ID: 30054755
[TBL] [Abstract][Full Text] [Related]
10. High doses of atorvastatin and simvastatin induce key enzymes involved in VLDL production.
Roglans N; Verd JC; Peris C; Alegret M; Vázquez M; Adzet T; Díaz C; Hernández G; Laguna JC; Sánchez RM
Lipids; 2002 May; 37(5):445-54. PubMed ID: 12056585
[TBL] [Abstract][Full Text] [Related]
11. HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism.
Yu CY; Theusch E; Lo K; Mangravite LM; Naidoo D; Kutilova M; Medina MW
Hum Mol Genet; 2014 Jan; 23(2):319-32. PubMed ID: 24001602
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Chen Y; Ku H; Zhao L; Wheeler DC; Li LC; Li Q; Varghese Z; Moorhead JF; Powis SH; Huang A; Ruan XZ
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):365-76. PubMed ID: 24233489
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Pandyra AA; Mullen PJ; Goard CA; Ericson E; Sharma P; Kalkat M; Yu R; Pong JT; Brown KR; Hart T; Gebbia M; Lang KS; Giaever G; Nislow C; Moffat J; Penn LZ
Oncotarget; 2015 Sep; 6(29):26909-21. PubMed ID: 26353928
[TBL] [Abstract][Full Text] [Related]
14. Explication of interactions between HMGCR isoform 2 and various statins through In silico modeling and docking.
Karthik MV; Satya Deepak MV; Shukla P
Comput Biol Med; 2012 Feb; 42(2):156-63. PubMed ID: 22177940
[TBL] [Abstract][Full Text] [Related]
15. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
[TBL] [Abstract][Full Text] [Related]
16. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
[TBL] [Abstract][Full Text] [Related]
17. Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase.
Kato S; Smalley S; Sadarangani A; Chen-Lin K; Oliva B; Brañes J; Carvajal J; Gejman R; Owen GI; Cuello M
J Cell Mol Med; 2010 May; 14(5):1180-93. PubMed ID: 19432822
[TBL] [Abstract][Full Text] [Related]
18. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
19. Human hydroxymethylglutaryl-coenzyme A reductase (HMGCR) and statin sensitivity.
Jawaid S; Gertz M; Corsino C; Cheung J; Seidle H; Couch RD
Indian J Biochem Biophys; 2010 Dec; 47(6):331-9. PubMed ID: 21355415
[TBL] [Abstract][Full Text] [Related]
20. CYP11A1 silencing suppresses HMGCR expression via cholesterol accumulation and sensitizes CRPC cell line DU-145 to atorvastatin.
Tashiro J; Sugiura A; Warita T; Irie N; Dwi Cahyadi D; Ishikawa T; Warita K
J Pharmacol Sci; 2023 Nov; 153(3):104-112. PubMed ID: 37770151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
